Pharmaceutical Executive-11-01-2020

SynBio opens new environmental sustainability possibilities for pharma.

Especially critical amid the continuing global pandemic, key metrics are laid out to help life sciences companies define, measure, and effectively communicate sustainability practices and progress—and build foundations for long-term business value.

Matt Ros, EVP, chief strategy and business officer of Epizyme, talks to Pharm Exec about his career in oncology and his role in transforming an epigenetics R&D company into a fully integrated commercial business.

Chief financial officers gather virtually to share the stories of directing their company IPOs over the finish line amid the COVID-19 pandemic.

The importance of life sciences companies focused on rare diseases to take early steps to bridge connections with patients, caregivers, and healthcare providers.

How the pandemic helped prove a point.

A brief look into how the Gene Editing Institute researching the diversity of responses in African-American regenerative cells to various forms of CRISPR.

Following her own experience, a health tech entrepreneur turned to AI to better guide other patients through their treatment journeys.

Authorities fear distrust of early preventives and complications for ongoing COVID-19 research.

Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.

Must maintain trust in face of customary, non-pandemic challenges.

A check on the evolving challenges and potential solutions in steering future market adoption of curative-intended treatments.

Lessons to launch by during a pandemic—or otherwise.

Biopharma raises an unprecedented $100 billion.

Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.